DIRECT ANSWER
Evidence-based answer.
Both are promoted for recovery far beyond the human evidence. The main differences are the shape of the preclinical literature and the identity problem around TB-500.
Reviewed August 7, 2026. Each statement links to its evidence record, followed by the primary and official sources used for this answer.
01Evidence point 1
BPC-157 has broad animal and laboratory findings but no established human efficacy program for recovery claims.
Open evidence record02Evidence point 2
TB-500 claims often borrow evidence from full-length thymosin beta-4 even though those entities should not be treated as interchangeable.
Open evidence record03Evidence point 3
Neither is FDA approved, and both are prohibited for athletes under the current WADA framework.
Open evidence recordPRIMARY & OFFICIAL SOURCES
Sources for this answer.
4 source records, with duplicates removed.